Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

INTRODUCTION: We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of −12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabbiani, Massimiliano, Di Giambenedetto, Simona, Quiros-Roldan, Eugenia, Latini, Alessandra, Vullo, Vincenzo, Antinori, Andrea, Castagna, Antonella, Orofino, Giancarlo, Francisci, Daniela, Grilli, Elisabetta, Madeddu, Giordanu, Grima, Pierfrancesco, Rusconi, Stefano, Del Pin, Barbara, Mondi, Annalisa, Borghetti, Alberto, Focà, Emanuele, Colafigli, Manuela, De Luca, Andrea, Cauda, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P276
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225257/
https://www.ncbi.nlm.nih.gov/pubmed/25397552
http://dx.doi.org/10.7448/IAS.17.4.19808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225257/
https://www.ncbi.nlm.nih.gov/pubmed/25397552
http://dx.doi.org/10.7448/IAS.17.4.19808

Ejemplares similares